🇺🇸 FDA
Patent

US 7585841

Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src

granted A61KA61K38/00A61K48/00

Quick answer

US patent 7585841 (Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Sep 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Sep 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/00, A61K48/00, A61P, A61P19/02